| Name | Title | Contact Details |
|---|
ProSomnus is the first manufacturer of precision, mass-customized Precision Oral Appliance Therapy devices to treat OSA, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. ProSomnus`s patented devices are a more comfortable and less invasive alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to more effective and patient-preferred outcomes. With more than 150,000 patients treated, ProSomnus`s devices are the most prescribed Precision Oral Appliance Therapy in the U.S.
angiomax is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Modern lifestyles and persistent near vision utilization cause a majority of patients to experience the reduced visual acuity and painful symptoms of eye misalignment – headaches, eye strain, neck and shoulder pain, motion sickness and dry eye sensation. Neurolens addresses common binocular vision issues using a three-step process. Step one is efficiently identifying patient symptomology using a basic online symptom screener that every patient can complete in minutes. This information goes directly to the Neurolens Measurement Device, Gen 2—or NMD2—ready for step two, which is accurately and objectively measuring the patient`s level of misalignment. The NMD2 is an objective, accurate and repeatable way to measure eye misalignment as small as 0.01 Prism Diopters. Most importantly, step three is correcting eye misalignment with a proven lens solution. Neurolenses address binocular vision issues by providing a contoured prism lens design that gradually delivers more prism in the lens corridor from distance to near. Neurolenses are proven to have a profound impact on a patient`s visual clarity and comfort. In fact, 93% of patients responded positively to wearing Neurolenses. Over 81% of patients suffering from chronic daily headaches reported their symptoms were substantially reduced or basically gone after wearing Neurolenses for 90 days. Neurolens—recognized in 2022 as one of the 30 fastest growing private companies in the healthcare industry by Inc. Magazine—is confident that appropriately addressing growing binocular vision issues will become a standard of care in this industry, unlocking dramatic patient outcomes and practice growth.
Montclair Plaza Dental Group is a Montclair, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IDC is a global medical imaging technology provider and innovative force in the high growth field of digital radiography (DR) technology. The Company has over 3,000 installations in 50 countries of its proprietary, award winning direct capture DR technology, which replaces conventional film-based diagnostic imaging and provides a cost-effective solution for medical facilities of all sizes to provide high quality diagnostic X-ray images and improve the level of healthcare for their patients. Throughout its history, IDC has been recognized by multiple industry organizations and research analysts such as: Frost & Sullivan and Deloitte Technology; for its dedication to innovation, global market growth, and customer focused value proposition. The Company has its corporate office in Calgary, Canada, a business office in Hong Kong, and a representative office in Beijing, China.